Abstract 4678: Unexpected lack of activity of Bardoxolone (5MeCDDO) in progression period of rodent models of breast, intestinal and head and neck cancers. What does it mean for the ARE as a primary prevention target.

The preventive efficacy of the triterpenoid 5MeCDDO was evaluated in multiple preclinical models of cancer. This included three models of breast cancer, the Min mouse model of intestinal cancer, and the 4-nitroquinoline-1-oxide (4NQO) induced model of head and neck cancer. In the ER+ model of breast cancer, Sprague Dawley rats were administered MNU, i.v., at 50 days of age and 5MeCDDO (27 ppm) was administered in the diet beginning 5 days post...